SAN

85.61

-0.21%↓

MRK1

115.25

-0.52%↓

ARGX

785

-0.36%↓

PHIA

24.21

-0.12%↓

ONC.US

340.64

+1.61%↑

SAN

85.61

-0.21%↓

MRK1

115.25

-0.52%↓

ARGX

785

-0.36%↓

PHIA

24.21

-0.12%↓

ONC.US

340.64

+1.61%↑

SAN

85.61

-0.21%↓

MRK1

115.25

-0.52%↓

ARGX

785

-0.36%↓

PHIA

24.21

-0.12%↓

ONC.US

340.64

+1.61%↑

SAN

85.61

-0.21%↓

MRK1

115.25

-0.52%↓

ARGX

785

-0.36%↓

PHIA

24.21

-0.12%↓

ONC.US

340.64

+1.61%↑

SAN

85.61

-0.21%↓

MRK1

115.25

-0.52%↓

ARGX

785

-0.36%↓

PHIA

24.21

-0.12%↓

ONC.US

340.64

+1.61%↑

Search

Fagron

Atidarymo kaina

SektoriusSveikatos priežiūra

21.05

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21

Max

21.25

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.4M

46M

Pardavimai

34M

476M

P/E

Sektoriaus vid.

17.992

79.874

Dividendų pajamingumas

1.69

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

16M

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.69%

2.31%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

96M

1.5B

Ankstesnė atidarymo kaina

21.05

Ankstesnė uždarymo kaina

21.05

Naujienos nuotaikos

By Acuity

50%

50%

168 / 374 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-27 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

2025-11-27 15:32; UTC

Įsigijimai, susijungimai, perėmimai

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

2025-11-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

2025-11-27 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-27 16:05; UTC

Rinkos pokalbiai

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

2025-11-27 16:04; UTC

Rinkos pokalbiai

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

2025-11-27 15:54; UTC

Įsigijimai, susijungimai, perėmimai

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

2025-11-27 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: No Certainty Talks Will Result in Transaction

2025-11-27 15:43; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

2025-11-27 15:42; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

2025-11-27 15:41; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

2025-11-27 15:11; UTC

Rinkos pokalbiai

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

2025-11-27 14:26; UTC

Rinkos pokalbiai

Hermes' Outperformance Gap Could Narrow -- Market Talk

2025-11-27 14:11; UTC

Rinkos pokalbiai

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

2025-11-27 14:11; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-11-27 13:35; UTC

Rinkos pokalbiai

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

2025-11-27 13:33; UTC

Rinkos pokalbiai

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

2025-11-27 13:22; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-27 13:22; UTC

Rinkos pokalbiai

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

2025-11-27 13:17; UTC

Rinkos pokalbiai

LVMH Should Be Able to Recover Next Year -- Market Talk

2025-11-27 11:13; UTC

Rinkos pokalbiai

European Gas Prices Come Under Pressure -- Market Talk

2025-11-27 11:07; UTC

Uždarbis

Genting: Positive About Prospects Over Longer Term

2025-11-27 11:06; UTC

Uždarbis

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

2025-11-27 11:04; UTC

Uždarbis

Genting: International Travel Demand Expected to Remain Resilient

2025-11-27 11:04; UTC

Uždarbis

Genting: Global Growth Expected to Remain Subdued

2025-11-27 11:04; UTC

Uždarbis

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

2025-11-27 10:59; UTC

Uždarbis

Genting Bhd 3Q Net Profit Fell 86% on Year

2025-11-27 10:58; UTC

Uždarbis

Genting Bhd 3Q Rev Rose 14% on Year

2025-11-27 10:56; UTC

Uždarbis

Genting Bhd 3Q Net MYR30.3M

2025-11-27 10:56; UTC

Uždarbis

Genting Bhd 3Q EPS MYR0.0079

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

168 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat